Endometrial hyperplastic diseases remain among the most prevalent gynecological conditions and are characterized by an altered glandular-to-stromal ratio resulting from changes in endometrial hormonal responsiveness. According to published data, hyperplastic processes account for 15–40% of all gynecological disorders and frequently represent precancerous conditions, particularly in cases of prolonged unopposed estrogen exposure without adequate progesterone opposition. Objective. To determine clinical and anamnestic characteristics as well as immunohistochemical markers in women with endometrial hyperplasia to predict the risk of neoplastic progression. Materials and methods. A prospective randomized cohort study enrolled 130 women of reproductive age, who were divided into three groups based on endometrial morphology. Group I comprised 80 women with non-atypical endometrial hyperplasia; Group II included 30 women with confirmed atypical endometrial hyperplasia; Group III in the control group consisted of 20 women with abnormal uterine bleeding (AUB), classified according to the PALM-COEIN system and attributed to causes other than endometrial hyperplasia. A comprehensive medical history was obtained for all participants. Gynecological status, concomitant diseases, and details of prior surgical interventions were evaluated. Patients in Groups I and II underwent hysteroresectoscopy after clinical diagnosis, whereas Group III underwent endometrial Pipelle biopsy. The obtained endometrial samples were examined by pathomorphological and immunohistochemical methods to assess the expression of the following markers: Ki-67, PTEN, CD138, p53, estrogen receptor alpha (ERα), and progesterone receptor (PR). Results. Analysis of anamnestic data revealed that women with atypical endometrial hyperplasia had a significantly higher mean age (55.2 ± 1.42 years) compared with the other groups (35.6 ± 1.22 years and 37.2 ± 1.65 years, respectively; p < 0.005). Early menarche (9–11 years of age) was documented in 30.0% of women with atypical endometrial hyperplasia, and early sexual debut (≤16 years of age) was recorded in 53.3% of these patients. Most women with atypical endometrial hyperplasia (49.0%) did not use contraception, and infertility was diagnosed in 29.0% of them. Cervical pathology was detected significantly more frequently (11.7%), and chronic endometritis was identified in 33.3% of cases (p < 0.05). The most prevalent comorbidities in patients with endometrial hyperplasia with atypia included obesity (30.0%), arterial hypertension (33.0%), type 2 diabetes mellitus (29.0%), and posthemorrhagic anemia (31.0%). Immunohistochemical analysis demonstrated increased Ki-67 expression, a marked decrease or complete loss of PTEN expression, a mutational (nuclear) pattern of p53 expression, positive CD138 immunoreactivity, and reduced endometrial sensitivity to progesterone. Patients with endometrial hyperplasia without atypia were characterized by preserved PTEN expression, increased proliferation as assessed by Ki-67, and the presence of CD138-positive plasma cells. Conclusions. 1. Atypical endometrial hyperplasia is more frequently associated with advanced age, early menarche, and early sexual debut, factors that may contribute to chronic inflammation and subsequent atypical endometrial transformation. 2. Chronic endometritis was identified in a substantial proportion of patients in both groups, supporting its role in the pathogenesis of hyperplastic endometrial changes; additional risk factors include obesity, arterial hypertension, diabetes mellitus, and repeated intrauterine interventions. 3. Endometrial hyperplasia without atypia is typically characterized by preserved PTEN expression and a moderate increase in Ki-67 proliferation index, whereas the atypical form exhibits high proliferative activity (Ki-67), PTEN loss, and a mutational p53 pattern, indicating elevated neoplastic risk. 4. CD138 serves as a marker of endometrial inflammation and microbial colonization and was detected with comparable frequency in endometrial samples from women with endometrial hyperplasia without atypia and with atypia. Assessment of endometrial estrogen receptor alpha (ERα) and progesterone receptor (PR) expression is essential for predicting hormonal responsiveness and guiding therapeutic selection.